Open AccessT lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell‐cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE)
Author(s) -
LEVY E.,
AMBRUS J.,
KAHL L.,
MOLINA H.,
TUNG K.,
HOLERS V. M.
Publication year - 1992
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1992.tb07935.x
Subject(s) - immunology , cd3 , complement receptor , jurkat cells , t cell , lymphocyte , flow cytometry , complement system , cd8 , biology , antibody , antigen , immune system
SUMMARY Complement receptor 2 (CR2, CD21), the receptor for both the C3d,g portion of human complement component C3 and the Epstein‐Barr virus, has been recently described on peripheral T cells. By using dual stain flow cytometric analysis, we have also observed that a peripheral T lymphocyte subpopulation of normal healthy donors bears CR2 in a range varying from 1.1 to 23/2% (mean 12.6%) of total CD3 + cells. T lymphocytes from nine patients with inactive SLE expressed CR2 in a similar range. Three patients with active SLE were also studied. One of them, having neuropathy and glomerulonephritis, displayed an expansion of the CR2 + T cell subpopulation which reached as much as 89% of total CD3 + cells. To examine potential functional roles of T cell CR2, cells from a Jurkat‐derived CR2 expressing T cell line were found to bind in vitro to human CR2 − , complement‐coated K562 cell targets in a CR2‐ and complement‐dependent fashion. Based on these studies, we hypothesize that CR2 might act to increase adherence of T cells to nucleated target cells bearing C3d,g, a function which may be relevant to cytotoxicity or other T cell activities requiring cell‐cell interaction.